Literature DB >> 17442219

The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy.

Murray Epstein1, David A Calhoun.   

Abstract

Resistant hypertension constitutes an increasingly common medical disorder. Although the exact incidence is not precisely known, estimates derived from recent outcome studies emphasize that resistant hypertension is much more common than previously thought. A major advance in our understanding of its pathogenesis and management is the recent recognition of the importance of aldosterone excess or autonomy as an important mechanism for drug resistance in hypertension. Recent studies of the effects of aldosterone on vascular smooth muscle have delineated several extra-renal mechanisms whereby aldosterone produces hypertension primarily by its direct vasoconstrictor effects and by altering vascular compliance. Consequently, aldosterone blockade constitutes an effective intervention for treating resistant hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442219     DOI: 10.1007/s11906-007-0018-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


  52 in total

Review 1.  The pathophysiology of aldosterone in the cardiovascular system.

Authors:  Ricardo Rocha; John W Funder
Journal:  Ann N Y Acad Sci       Date:  2002-09       Impact factor: 5.691

Review 2.  Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension.

Authors:  Chandan Saha; George J Eckert; Walter T Ambrosius; Tae-Yon Chun; Mary Anne Wagner; Qianqian Zhao; J Howard Pratt
Journal:  Hypertension       Date:  2005-08-22       Impact factor: 10.190

3.  Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.

Authors:  Michael E Ernst; Barry L Carter; Chris J Goerdt; Jennifer J G Steffensmeier; Beth Bryles Phillips; M Bridget Zimmerman; George R Bergus
Journal:  Hypertension       Date:  2006-01-23       Impact factor: 10.190

4.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

5.  Aldosterone activates Na+/H+ exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms.

Authors:  S Ebata; S Muto; K Okada; J Nemoto; M Amemiya; T Saito; Y Asano
Journal:  Kidney Int       Date:  1999-10       Impact factor: 10.612

6.  Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells.

Authors:  M Wehling; C B Neylon; M Fullerton; A Bobik; J W Funder
Journal:  Circ Res       Date:  1995-06       Impact factor: 17.367

7.  Efficacy of low-dose spironolactone in subjects with resistant hypertension.

Authors:  Mari Konishi Nishizaka; Mohammad Amin Zaman; David A Calhoun
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

8.  Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region.

Authors:  B Strauch; T Zelinka; M Hampf; R Bernhardt; J Widimsky
Journal:  J Hum Hypertens       Date:  2003-05       Impact factor: 3.012

9.  Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman; W G Henderson
Journal:  J Hum Hypertens       Date:  1995-10       Impact factor: 3.012

10.  Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells.

Authors:  M Christ; K Douwes; C Eisen; G Bechtner; K Theisen; M Wehling
Journal:  Hypertension       Date:  1995-01       Impact factor: 10.190

View more
  7 in total

1.  Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome.

Authors:  Melvin R Hayden; James R Sowers
Journal:  J Am Soc Hypertens       Date:  2008-06-02

2.  Baroreflex gain and vasomotor sympathetic modulation in resistant hypertension.

Authors:  Isabelle Magalhães Guedes Freitas; Leonardo Barbosa de Almeida; Natália Portela Pereira; Pedro Augusto de Carvalho Mira; Rogério Baumgratz de Paula; Daniel Godoy Martinez; Edgar Toschi-Dias; Mateus Camaroti Laterza
Journal:  Clin Auton Res       Date:  2017-04-06       Impact factor: 4.435

3.  Resistant hypertension workup and approach to treatment.

Authors:  Anastasios Makris; Maria Seferou; Dimitris P Papadopoulos
Journal:  Int J Hypertens       Date:  2010-12-26       Impact factor: 2.420

4.  Clinical approach in treatment of resistant hypertension.

Authors:  Jennifer Frank; David Sommerfeld
Journal:  Integr Blood Press Control       Date:  2009-07-30

Review 5.  Well tolerated spironolactone-related hyponatremia.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-04       Impact factor: 3.738

6.  Clinical and pathological analysis of the kidney in patients with hypertensive nephropathy.

Authors:  Xiang-Chuan Wang; Chun-Hui Liu; Yun-Jing Chen; Yang Wu; Lei-Shan Yang; Hong-Min Liu; Hai-Li Liao
Journal:  Exp Ther Med       Date:  2013-09-18       Impact factor: 2.447

Review 7.  Molecular Mechanisms of Primary Aldosteronism.

Authors:  Sergei G Tevosian; Shawna C Fox; Hans K Ghayee
Journal:  Endocrinol Metab (Seoul)       Date:  2019-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.